These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37644779)

  • 1. The characteristics and outcomes in patients with acute heart failure who used tolvaptan: from KCHF registry.
    Nishikawa R; Kato T; Morimoto T; Yaku H; Inuzuka Y; Tamaki Y; Yamamoto E; Ozasa N; Tada T; Sakamoto H; Seko Y; Shiba M; Yoshikawa Y; Yamashita Y; Kitai T; Taniguchi R; Iguchi M; Nagao K; Kawai T; Komasa A; Kawase Y; Morinaga T; Toyofuku M; Furukawa Y; Ando K; Kadota K; Sato Y; Kuwahara K; Kimura T;
    ESC Heart Fail; 2023 Oct; 10(5):3141-3151. PubMed ID: 37644779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public assistance in patients with acute heart failure: a report from the KCHF registry.
    Nishimoto Y; Kato T; Morimoto T; Taniguchi R; Yaku H; Inuzuka Y; Tamaki Y; Yamamoto E; Yoshikawa Y; Kitai T; Iguchi M; Kato M; Takahashi M; Jinnai T; Ikeda T; Nagao K; Kawai T; Komasa A; Nishikawa R; Kawase Y; Morinaga T; Su K; Kawato M; Seko Y; Inoko M; Toyofuku M; Furukawa Y; Nakagawa Y; Ando K; Kadota K; Shizuta S; Ono K; Kuwahara K; Ozasa N; Sato Y; Kimura T
    ESC Heart Fail; 2022 Jun; 9(3):1920-1930. PubMed ID: 35289117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-reactive protein at discharge and 1-year mortality in hospitalised patients with acute decompensated heart failure: an observational study.
    Nishimoto Y; Kato T; Morimoto T; Yaku H; Inuzuka Y; Tamaki Y; Yamamoto E; Yoshikawa Y; Kitai T; Taniguchi R; Iguchi M; Kato M; Takahashi M; Jinnai T; Ikeda T; Nagao K; Kawai T; Komasa A; Nishikawa R; Kawase Y; Morinaga T; Su K; Kawato M; Seko Y; Inoko M; Toyofuku M; Furukawa Y; Nakagawa Y; Ando K; Kadota K; Shizuta S; Ono K; Kuwahara K; Ozasa N; Sato Y; Kimura T
    BMJ Open; 2020 Dec; 10(12):e041068. PubMed ID: 33376169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of the Severity of Clinical Congestion in Patients Hospitalized for Decompensated Heart Failure: Findings From the Japanese KCHF Registry.
    Aida K; Nagao K; Kato T; Yaku H; Morimoto T; Inuzuka Y; Tamaki Y; Yamamoto E; Yoshikawa Y; Kitai T; Taniguchi R; Iguchi M; Kato M; Takahashi M; Jinnai T; Kawai T; Komasa A; Nishikawa R; Kawase Y; Morinaga T; Su K; Kawato M; Seko Y; Inada T; Inoko M; Toyofuku M; Furukawa Y; Nakagawa Y; Ando K; Kadota K; Shizuta S; Ono K; Sato Y; Kuwahara K; Ozasa N; Kimura T
    J Card Fail; 2023 Aug; 29(8):1150-1162. PubMed ID: 36690136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Good response to tolvaptan shortens hospitalization in patients with congestive heart failure.
    Kogure T; Jujo K; Hamada K; Saito K; Hagiwara N
    Heart Vessels; 2018 Apr; 33(4):374-383. PubMed ID: 29128962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of door-to-tolvaptan time on short-term clinical outcome in patients with acute heart failure.
    Nomura R; Morishita T; Sato Y; Aoyama D; Shimizu T; Uzui H; Nakano A; Tada H
    ESC Heart Fail; 2023 Dec; 10(6):3573-3581. PubMed ID: 37752742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction.
    Matsue Y; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; Goldsmith SR
    J Card Fail; 2016 Jun; 22(6):423-32. PubMed ID: 26915749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporal trends in tolvaptan use after revision of national heart failure guidelines in Japan.
    Yamazaki Y; Shiraishi Y; Kohsaka S; Nagatomo Y; Fukuda K; Kohno T; Yoshikawa T
    Sci Rep; 2021 Sep; 11(1):19360. PubMed ID: 34588492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolvaptan vs. furosemide-based diuretic regimens in patients hospitalized for heart failure with hyponatremia (AQUA-AHF).
    Ng TMH; Grazette LP; Fong MW; Yoon AJ; Lou M; Kuo A; Upadhyay RY; Han EE; Mehra A; Elkayam U
    ESC Heart Fail; 2020 Aug; 7(4):1927-1934. PubMed ID: 32543020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Tolvaptan in Patients More Than 90 Years Old With Acute Heart Failure.
    Sato Y; Uzui H; Mukai M; Shiomi Y; Hasegawa K; Ikeda H; Tama N; Fukuoka Y; Morishita T; Ishida K; Kaseno K; Miyazaki S; Nakano A; Tada H
    J Cardiovasc Pharmacol Ther; 2020 Jan; 25(1):47-56. PubMed ID: 31280620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
    Konstam MA; Gheorghiade M; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1319-31. PubMed ID: 17384437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial).
    Vaduganathan M; Greene SJ; Ambrosy AP; Mentz RJ; Subacius HP; Chioncel O; Maggioni AP; Swedberg K; Zannad F; Konstam MA; Senni M; Givertz MM; Butler J; Gheorghiade M;
    Am J Cardiol; 2014 Dec; 114(11):1713-21. PubMed ID: 25312638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure.
    Felker GM; Mentz RJ; Cole RT; Adams KF; Egnaczyk GF; Fiuzat M; Patel CB; Echols M; Khouri MG; Tauras JM; Gupta D; Monds P; Roberts R; O'Connor CM
    J Am Coll Cardiol; 2017 Mar; 69(11):1399-1406. PubMed ID: 27654854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newly Diagnosed Infection After Admission for Acute Heart Failure: From the KCHF Registry.
    Seko Y; Kato T; Morimoto T; Yaku H; Inuzuka Y; Tamaki Y; Ozasa N; Shiba M; Yamamoto E; Yoshikawa Y; Yamashita Y; Kitai T; Taniguchi R; Iguchi M; Nagao K; Jinnai T; Komasa A; Nishikawa R; Kawase Y; Morinaga T; Toyofuku M; Furukawa Y; Ando K; Kadota K; Sato Y; Kuwahara K; Kimura T;
    J Am Heart Assoc; 2021 Nov; 10(22):e023256. PubMed ID: 34730004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Right ventricular contractility affects the clinical efficacy of add-on tolvaptan following hospitalization for heart failure in patients with significant tricuspid regurgitation.
    Hachiya R; Mochizuki Y; Shibakai M; Omomo Y; Kuroki Y; Endo Y; Ichikawa S; Miyazaki H; Chino S; Toyosaki E; Ota M; Fukuoka H; Shinke T
    Heart Vessels; 2022 May; 37(5):755-764. PubMed ID: 34677658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size.
    Toda H; Nakamura K; Nakahama M; Wada T; Watanabe A; Hashimoto K; Terasaka R; Tokioka K; Nishii N; Miyoshi T; Kohno K; Kawai Y; Miyaji K; Koide Y; Tachibana M; Yoshioka R; Ito H;
    J Cardiol; 2016 Feb; 67(2):177-83. PubMed ID: 26072263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
    Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
    JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of in-hospital mortality in elderly patients with heart failure treated with tolvaptan.
    Kobayashi M; Hayashi M; Yamada R; Ishiguro T; Fujiwara W; Ishii H; Naruse H; Watanabe E; Ozaki Y; Izawa H
    Fujita Med J; 2023 May; 9(2):80-83. PubMed ID: 37234387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renoprotective effect of tolvaptan in patients with new-onset acute heart failure.
    Kin H; Matsumura K; Yamamoto Y; Fujii K; Otagaki M; Takahashi H; Park H; Yoshioka K; Yokoi M; Sugiura T; Shiojima I
    ESC Heart Fail; 2020 Aug; 7(4):1764-1770. PubMed ID: 32383323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
    Gheorghiade M; Konstam MA; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1332-43. PubMed ID: 17384438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.